On Friday night, after the markets closed, Johnson & Johnson
Should shareholders be worried? It's hard to tell. In typical pharma fashion -- yeah, I'm looking at you, GlaxoSmithKline
If you read between the lines, this could be bad news for Johnson & Johnson. When the FDA turned down the marketing application for its anticoagulant Xarelto in May, Johnson & Johnson didn't say exactly what additional information the FDA wanted, but did mention that no additional clinical trials were needed. Friday's press release about carisbamate had no such clause, leading me to wonder whether the FDA will require further testing.
It's a stretch, but what else do investors have to go on? Especially when J&J's press release includes useless comments like this one: "The company is currently evaluating the FDA's complete response letter, and will respond to the agency's questions as quickly as possible."
We should hope so.
Carisbamate failed one of its clinical trials, which tested its ability to lower the frequency of seizure when added to other epilepsy drugs. The class includes Abbott Labs'
With U.S. sales of its blockbuster epilepsy drug, Topamax, down 86% last quarter after Topamax started facing generic competition, Johnson & Johnson could really use an approval to replace it. Unfortunately, the FDA may try to squeeze a little more data out of Johnson & Johnson, and responding "as quickly as possible" may take some time.
Johnson & Johnson is an Income Investor recommendation. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.
More from The Motley Fool
These 2 Developments Could Accelerate Johnson & Johnson's Next Acquisition
A double-whammy of bad news just might help encourage J&J to go back into acquisition mode.
3 Dividend Stocks That Pay Out Over $8 Billion a Year
Can these huge companies keep the big dividend bucks flowing?
Johnson & Johnson Aims to Start 2018 Healthy
Investors have high hopes for the healthcare conglomerate.